Keyword: Bayer

A Bernstein analyst has previously said that breaking up crop and pharma would be the "best strategy" for Bayer.

Bayer is closing a plant in Germany and cutting loose 350 workers while moving to the U.S. production of hemophilia treatments made there.

A large-scale restructuring will touch every area of Bayer's business.

Bayer and its partner Loxo Oncology picked up FDA approval for their novel "tissue agnostic" TRK inhibitor Vitrakvi.

Two weeks after Bayer denied it might sell its consumer and animal health units, the company is reportedly meeting to discuss just that.

Bayer said meeting its 2018 forecasts for consumer health and animal health segments now seems increasingly ambitious.

Merck just advanced the Keytruda-Opdivo immuno-oncology rivalry into a brand-new arena.

A judge struck a large portion of a Roundup verdict against Bayer, but as thousands of lawsuits pile up, the litigation is just getting started.

The FDA approved Xarelto for chronic coronary or peripheral artery disease, an indication analysts said is worth $1.5 billion.

Bernstein analysts has recently figured selling animal health is "a real possibility" for Bayer and suggested management to consider it for pharma's sake.